Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion

被引:94
作者
Rigolin, GM
Fraulini, C
Ciccone, M
Mauro, E
Bugli, AM
De Angeli, C
Negrini, M
Cuneo, A
Castoldi, G
机构
[1] Univ Ferrara, Dept Biomed Sci, Hematol Sect, Azienda Osped Univ Arcisped S Anna, I-44100 Ferrara, Italy
[2] Univ Ferrara, Microbiol Sect, Ferrara, Italy
[3] Univ Ferrara, Dept Expt & Diagnost Med, Ferrara, Italy
[4] Univ Ferrara, Ctr Interdipartimentale Ric Cancro, Ferrara, Italy
关键词
D O I
10.1182/blood-2005-04-1768
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In multiple myeloma (MM). circulating endothelial cells (CECs) represent a vascular marker of angiogenesis and may reflect tumor mass. In this report, we showed that, in 5 MM patients with 13q14 deletion, CECs carried the same chromosome aberration as the neoplastic plasma cells (11%-32% of CECs with 13q14 deletion). Most of the CECs displayed immunophenotypic features of endothelial pro-genitor cells as they expressed CD133, a marker gradually lost during endothelial differentiation and absent on mature endothelial cells. To the contrary, in 3 patients with monoclonal gammopathy of undetermined significance and 13q14 deletion, CECs were cytogenetically normal and had a mature immunophenotype. In MM CECs, immunoglobulin genes were clonally rearranged. These findings suggest a possible origin of CECs from a common hemangioblast precursor that can give rise to both plasma cells and endothelial cells and point to a direct contribution of MM-derived CECs to tumor vasculogenesis and possibly to the spreading and progression of the disease.
引用
收藏
页码:2531 / 2535
页数:5
相关论文
共 21 条
[1]   S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen [J].
Bardin, N ;
George, F ;
Mutin, M ;
Brisson, C ;
Horschowski, M ;
Frances, V ;
Lesaule, G ;
Sampol, J .
TISSUE ANTIGENS, 1996, 48 (05) :531-539
[2]   Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients [J].
Beerepoot, LV ;
Mehra, N ;
Vermaat, JSP ;
Zonnenberg, BA ;
Gebbink, MFGB ;
Voest, EE .
ANNALS OF ONCOLOGY, 2004, 15 (01) :139-145
[3]   New drugs for treatment of multiple myeloma [J].
Bruno, B ;
Rotta, M ;
Giaccone, L ;
Massaia, M ;
Bertola, A ;
Palumbo, A ;
Boccadoro, M .
LANCET ONCOLOGY, 2004, 5 (07) :430-442
[4]   Mechanisms of angiogenesis and arteriogenesis [J].
Carmeliet, P .
NATURE MEDICINE, 2000, 6 (04) :389-395
[5]  
FIDEL IJ, 2004, NEW ENGL J MED, V351, P215
[6]   Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells [J].
Gunsilius, E ;
Duba, HC ;
Petzer, AL ;
Kähler, CM ;
Grünewald, K ;
Stockhammer, G ;
Gabl, C ;
Dirnhofer, S ;
Clausen, J ;
Gastl, G .
LANCET, 2000, 355 (9216) :1688-1691
[7]   Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma [J].
Hendrix, MJC ;
Seftor, EA ;
Hess, AR ;
Seftor, REB .
NATURE REVIEWS CANCER, 2003, 3 (06) :411-421
[8]   A new perspective on tumor endothelial cells: Unexpected chromosome and centrosome abnormalities [J].
Hida, K ;
Klagsbrun, N .
CANCER RESEARCH, 2005, 65 (07) :2507-2510
[9]   Advances in biology of multiple myeloma: clinical applications [J].
Hideshima, T ;
Bergsagel, PL ;
Kuehl, WM ;
Anderson, KC .
BLOOD, 2004, 104 (03) :607-618
[10]   CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer [J].
Hilbe, W ;
Dirnhofer, S ;
Oberwasserlechner, F ;
Schmid, T ;
Gunsilius, E ;
Hilbe, G ;
Wöll, E ;
Kähler, CM .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (09) :965-969